Voyager Therapeutics
75 Sidney Street
Cambridge
Massachusetts
02139
United States
Tel: 910-509-3977
Website: http://www.voyagertherapeutics.com/
111 articles with Voyager Therapeutics
-
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
11/19/2021
Voyager Therapeutics, Inc. today will present preclinical data demonstrating that IV dosing of a proprietary AAV vector identified by the TRACER™️ screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in models of HER2+ brain metastases.
-
Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
11/16/2021
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26th Society for Neuro-Oncology (SNO) Annual Meeting on Nov. 19, 2021.
-
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
11/2/2021
Voyager Therapeutics, Inc. today reported third quarter 2021 financial and operating results.
-
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
10/20/2021
Voyager Therapeutics, Inc. today announced the presentation of preclinical data demonstrating a single intravenous (IV) dose of its novel GBA1 gene replacement therapy
-
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
10/6/2021
Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties
-
Voyager Therapeutics entered a deal with Pfizer that allows Pfizer to exercise options to license novel capsids created by Voyager’s RNA-driven TRACER screening technology.
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences in September 2021
9/2/2021
Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation platform technologies, announced that it will participate in the following upcoming virtual investor conferences.
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences
8/10/2021
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following upcoming virtual investor conferences.
-
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
8/9/2021
Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation platform technologies, introduced new programs in Huntington’s disease, a monogenic form of ALS, spinal muscular atrophy, and diseases linked to GBA1 mutations, all powered by its proprietary AAV capsids that have demonstrated superior transgene expression in the brain compared to AAV9 delivery in non-human primates.
-
Voyager’s primary focus will be on developing gene therapies for Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and pre-clinical research in spinal muscular atrophy and diseases linked to GBA1 mutations.
-
Shares of Voyager Therapeutics fell in aftermarket trading after its CEO and CMO announced plans to depart the company following clinical setbacks with a Parkinson’s disease program.
-
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
5/19/2021
Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington’s disease and maximizing opportunities created by TRACERTM gene therapy technology platform and next-generation targeted AAV capsids
-
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
5/12/2021
Findings to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy Data demonstrate durable expression in CNS and may represent a new single-dose therapeutic strategy for treating various tauopathies
-
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
5/11/2021
Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration
-
The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here’s a look at a few of the highlights.
-
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
5/10/2021
- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference, including new data on next generation blood brain barrier penetrant capsids - Virtual investor and analyst event to be held in July 2021
-
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
4/28/2021
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 24 th Annual Meeting taking place virtually on May 11-14, 2021. Oral presentations include the first reporting on the company’s novel capsid technology.
-
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
4/26/2021
One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year
-
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
2/25/2021
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases, today reported its fourth quarter and full year 2020 financial results and provided corporate updates.
-
Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
2/18/2021
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2020 financial results after market close on Thursday, February 25, 2021